{
    "title": "Selenium vs Cancer",
    "inventor_name": "Dr Emanuel Revici",
    "publication_year": null,
    "device_name": null,
    "goal": "Treat cancer and other diseases by correcting lipid metabolic imbalances with non-toxic lipid-based compounds and trace-element (e.g., selenium) therapeutics.",
    "problem_addressed": "Advanced-stage cancers and other chronic diseases caused by anabolic/catabolic imbalance and abnormal lipid metabolism.",
    "concept_summary": "Revici's \"guided lipid\" therapy uses specially prepared lipids, fatty acids, sterols and trace-element-metallic compounds (notably a bivalent-negative form of selenium) to restore the body's anabolic-catabolic balance. The compounds are claimed to have a natural affinity for tumor tissue, delivering therapeutic elements directly to malignant cells while remaining non-toxic.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Anabolic-catabolic balance theory",
        "Lipid-based drug delivery",
        "Trace-element (selenium) incorporation into fatty acids",
        "Guided chemotherapy individualized to metabolic tests"
    ],
    "scientific_domains": [
        "Biochemistry",
        "Oncology",
        "Pharmacology",
        "Medical Chemistry"
    ],
    "mechanisms_of_action": [
        "Restores lipid metabolic balance",
        "Delivers selenium-laden lipid molecules that preferentially accumulate in tumor tissue",
        "Incorporates low-toxicity metallic elements into unsaturated fatty acids",
        "Modulates anabolic/catabolic signaling pathways"
    ],
    "materials": [
        "Lipids",
        "Fatty acids",
        "Sterols (e.g., cholesterol)",
        "Selenium (bivalent-negative form)",
        "Copper",
        "Sulfur",
        "Zinc",
        "Calcium",
        "Nickel",
        "Beryllium",
        "Mercury",
        "Lead"
    ],
    "energy_sources": [],
    "inputs": [
        "Patient metabolic/urine diagnostic results (pH, specific gravity, surface tension, chloride index)",
        "Lipid-based therapeutic compounds",
        "Selenium-containing formulations"
    ],
    "outputs": [
        "Tumor regression or remission",
        "Pain reduction",
        "Improved overall health status"
    ],
    "claimed_performance": "Remission reported up to 20 years after treatment; case reports of terminal patients becoming cancer-free; reductions in tumor size and pain in a 140-patient study.",
    "experimental_evidence": "Case histories from the United States, France, Italy and Austria; a 140-patient study reported by Dr. R. Donaldson (1983) showing tumor size reduction and pain relief; nine of twelve terminal-cancer patients treated in Belgium showed significant improvements.",
    "replication_status": "Limited replication in European clinics (France, Italy, Austria) and isolated case reports; not widely accepted or validated by mainstream clinical trials.",
    "keywords": [
        "lipid therapy",
        "selenium cancer treatment",
        "guided chemotherapy",
        "trace element therapy",
        "alternative oncology"
    ],
    "related_technologies": [
        "Lipid-based drug delivery systems",
        "Trace-element supplementation",
        "Alternative cancer therapies"
    ],
    "controversy_level": "high",
    "confidence_score": 0.7,
    "practicability_score": 0.4,
    "fringe_score": 0.8,
    "evidence_strength": 0.4,
    "risk_score": 0.2,
    "trl_estimate": 4,
    "source_urls": [
        "http://drrevici.com",
        "http://www.healthy.net/Health/Article/Revici_Therapy/2013/3"
    ],
    "organizations": [
        "Institute of Applied Biology",
        "Trafalgar Hospital"
    ],
    "applications": [
        "Cancer treatment",
        "AIDS therapy",
        "Arthritis",
        "Alzheimer's disease",
        "Chronic pain",
        "Drug addiction"
    ],
    "limitations": [
        "Lack of randomized, peer-reviewed clinical trials",
        "Regulatory opposition and blacklist status",
        "Predominantly anecdotal evidence",
        "Potential variability in individual formulations"
    ],
    "open_questions": [
        "Exact biochemical mechanism of lipid-tumor affinity",
        "Optimal dosing and long-term safety of high-dose selenium compounds",
        "Reproducibility of results across diverse patient populations",
        "Standardization of diagnostic tests used to guide therapy"
    ],
    "red_flags": [
        "Listed as an unproven method by the American Cancer Society",
        "Historical legal challenges and license disputes",
        "Claims of high-dose selenium administration without extensive toxicology data"
    ],
    "evidence_quotes": [
        "\"In a 140-~patient study of cancer victims treated with selenium, Dr. R. Donaldson of the St. Louis Veterans' Administration Hospital reported in 1983 that some patients deemed terminal with only weeks to live were completely free of all signs of cancer after four years; all the patients showed a reduction in tumor size and in pain.\"",
        "\"The patient ... had no other treatment ... was cancer-free after cystoscopy in 1987.\"",
        "\"Nine of the twelve terminal-cancer patients on the Revici medicines, significant improvements occurred, including regression of tumors, disappearance of metastases, and cessation of hemorrhage.\"",
        "\"Revici's nontoxic chemotherapy uses lipids, lipid-based substances, and essential elements to correct an underlying imbalance in the patient's chemistry.\"",
        "\"Revici claims to have devised a novel technique to open double bonds in molecules of unsaturated fatty acids in order to incorporate different metallic elements at precise points in the molecules, resulting in therapeutic compounds with toxicity less than one-thousandth of the elemental forms.\""
    ]
}